SUNNYVALE, California,
April 11, 2017 /PRNewswire/ --
Premier Algerian Cancer
Center Now Provides Cancer Patients
with Leading-Edge Radiation Treatments
Accuray Incorporated (NASDAQ: ARAY) announced today that the
newly built Radiotherapy and Medical Oncology Center of
Sidi Abdellah, Algeria is now treating cancer patients with
the first TomoTherapy® Systems installed in Africa. The TomoTherapy System is recognized
worldwide for providing highly precise treatments for a broad range
of cancer cases, from routine to complex. The first treatment was
successfully delivered in February
2017 to a patient with breast cancer.
(Logo:
http://photos.prnewswire.com/prnh/20151126/291246LOGO )
(Photo:
http://mma.prnewswire.com/media/487840/Accuray.jpg )
The TomoTherapy Systems are two out of three Accuray systems to
be installed and operated at the Center, located not far from the
Technoparc of Sidi Abdellah in the
suburbs of Algiers. The
Radiotherapy and Medical Oncology Center also purchased one
CyberKnife® M6™ System which is scheduled to be installed by
the end of 2018. With the two systems - CyberKnife and TomoTherapy
- in one location, the Center will have the flexibility to
efficiently and effectively treat virtually all patients who may
benefit from this highly precise form of radiation therapy.
"We are honored that the Radiotherapy and Medical Oncology
Center team has selected the Accuray systems to expand their cancer
treatment options. Their decision reinforces growing global
recognition of the importance of radiation therapy in treating
cancer," said Lionel Hadjadjeba, MD, Corporate Senior Vice
President and President of Worldwide Commercial Operations at
Accuray. "The TomoTherapy and CyberKnife Systems provide an optimal
combination of efficacy and safety while minimizing the impact of
treatment on daily lives, and will enable the clinical team to
confidently provide each cancer patient with a treatment program
that addresses his or her individual needs."
In Algeria, 45,000 new cases of
cancer are diagnosed each year [1]. The acquisition of these new
technologies is in accordance with the Algerian Cancer Plan
2015-2019 which, among other measures, aims to improve the
performance of radiotherapy services, shorten times to obtain
radiotherapy appointments, and improve the quality and safety of
care in radiotherapy [1].
"I am very pleased and proud to offer, at the Radiotherapy and
Medical Oncology Center of Sidi
Abdellah, a full range of treatment options: from
chemotherapy to brachytherapy and now, treatment with the
TomoTherapy System. With this leading-edge and innovative radiation
therapy device, we can deliver precise, safe and individualized
radiation treatments to a wide range of tumor types while
preserving surrounding healthy tissue," said Prof. Mustapha Yaker, Director of the Radiotherapy and
Medical Oncology Center of Sidi
Abdellah. "Maintaining the patient's quality of life during
and post-treatment is a top priority and I believe the TomoTherapy
System will help us accomplish this goal."
Based on a CT scanner platform, the TomoTherapy System provides
continuous delivery of radiation from 360 degrees around the
patient, or delivery from clinician-specified beam angles. These
unique features, combined with daily 3D image guidance, enable
physicians to deliver highly accurate, individualized dose
distributions which precisely conform to the shape of the patient's
tumor while minimizing dose to normal, healthy tissue, resulting in
fewer side effects for patients. The TomoTherapy System is capable
of treating all standard radiation therapy indications including
breast, prostate, lung and head and neck cancers, in addition to
complex treatments such as total marrow irradiation.
The CyberKnife System delivers radiosurgery and stereotactic
body radiation therapy (SBRT), enabling precise, high quality dose
distributions to be confidently administered to the patient with
extreme accuracy over a minimum number of treatments, reducing side
effects and preserving patients' quality of life. Using its unique
robotic range of motion and continuous image guidance, the system
follows the target throughout the treatment process, delivering
individualized treatment with sub-millimeter precision.
About Accuray
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology
company that develops, manufactures, and sells precise, innovative
tumor treatment solutions that set the standard of care with the
aim of helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit http://www.accuray.com .
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, market acceptance of our new technologies,
patient outcomes and Accuray's leadership position in radiation
oncology innovation and technologies. Forward-looking statements
are subject to risks and uncertainties that could cause actual
results to differ materially from expectations, including but not
limited to the risks detailed from time to time under the heading
"Risk Factors" in the company's report on Form 10-K, filed on
August 24, 2016, the company's
reports on Form 10-Q, filed on November 1,
2016 and February 3, 2017, and
as updated periodically with the company's other filings with the
SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
References
- Zitouni M., Algeria's Cancer
Plan 2015-2019.
http://www.santemaghreb.com/algerie/comscien_pdf/cancer_plan_algerie_marrakech.pdf
- Atun F, et al. The Lancet Oncology Commission. Expanding
global access to radiotherapy. The Lancet Oncology 2015;
16(10):1153-86.